Medical Device Regulatory Fragmentation: When Innovation Is Held Hostage to Bureaucratic Multiplicity
Problem Definition
A medical device that could save lives is trapped in a 5-year global approval process — navigating separate regulatory systems with different requirements, evidence standards, and timelines. Manufacturers must submit the same device to 15+ regulatory agencies, each with unique documentation requirements, each taking 1-4 years.
The result: life-saving innovations reach patients 5+ years later than necessary. Patients die waiting. R&D resources are squandered on regulatory optimization rather than medical innovation. The fragmentation is not driven by legitimate differences in clinical contexts — it is bureaucratic path-dependence.
Root Causes
Each jurisdiction built its regulatory system independently without cross-border coordination
Regulators have institutional incentives to maintain autonomy and resist harmonization
Proof-of-concept for harmonization (EMA system) exists but has not been replicated globally
Developing countries lack technical capacity to implement advanced regulatory review, leading to isolation from global harmonization efforts
Device manufacturers lobby for status quo — they adapt to fragmentation and benefit from high barriers to entry